Stock Analysis
Sanofi (SNY) Stock Analysis
Sanofi (SNY) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Sanofi (SNY) currently has an AIQ Score of 68/100, indicating a bullish setup. Risk is the strongest factor at 85/100. Quality is the weakest current factor at 57/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
SNY at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $48.37 |
| AIQ Score | 68/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $115.76B |
| P/E Ratio (TTM) | 25.1 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $1.26 |
| Revenue (Q3 FY2026) | $15.23B |
| Dividend Yield (TTM) | 4.70% |
| Beta | 0.29 |
| Volume | 1.68M |
| 52-week range | $39.07-$52.68 |
| RSI 14 | 76.2 |
| 50-Day SMA | $42.68 |
| 200-Day SMA | $44.36 |
| Analyst Price Target | $57.00 |
| Next Earnings | Feb 4, 2027 |
SNYSanofi
Healthcare / Drug Manufacturers - General
Leader
Strong Relative Position
Latest quote
- Momentum64
- Value77
- Quality57
- Risk resilience85
- Sentiment—
SNY Stock Analysis Summary
Sanofi (SNY) currently has an AIQ Score of 68/100, indicating a bullish setup. Risk resilience is the strongest factor at 85/100. Quality is the weakest current factor at 57/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, SNY has AIQ Score of 68/100 with Risk resilience base of 85/100 and fading Quality at 57/100. Wait for component alignment before adding exposure.
Risk resilience (85/100) leads while Quality (57/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.19% stock move · SNY classified in Drug Manufacturers - General.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is SNY Bullish or Bearish Right Now?
SNY currently has a bullish overall setup. Risk Resilience is the strongest factor at 85/100, while Quality is weakest at 57/100. The current evidence suggests a constructive setup.
- - Risk Resilience is supportive at 85/100.
- - Price is +13.33% above its 50-day SMA.
- - Analyst target implies +17.84% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (35 vs 8).
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
SNY's Technical Analysis Consensus is currently Strong Buy, with 35 buy, 3 neutral, and 8 sell votes. SNY's 14-day RSI is 76.2, which places the stock in an overbought momentum range. SNY's beta is 0.29, indicating lower market sensitivity than the broad market.
What Changed in SNY?
The largest recent change in SNY is Momentum moving up by 6.0 points over the available 7-day comparison window. Risk Resilience remains the strongest visible factor.
What Would Change the SNY Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
SNY Decision Framework
Public evidence layers, setup checks, and risk context for Sanofi.
Sanofi (SNY) Stock Analysis
Sanofi has an AIQ Score of 68/100 in a Bullish regime. Risk is strongest at 85/100. Beta is 0.29, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | SNY is in a Bullish AIQ regime with score 68/100. |
| Signal Conflict | The primary conflict is that risk leads at 85/100 while quality lags at 57/100. |
| Factor Evidence | Momentum 64/100 · Value 77/100 · Quality 57/100 · Risk 85/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 85/100.
Momentum is 64/100 and RSI (14) is 76.2.
SNY is in a Bullish regime at 68/100.
Risk factor is 85/100 with beta 0.29 and annual volatility 24.14%.
Current conflict: risk leads at 85/100 while quality lags at 57/100.
SNY Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
SNY Fundamentals
SNY valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
SNY Technical Analysis
SNY technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
SNY Stock Catalysts
Track SNY earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
SNY Dividend Analysis
SNY dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
SNY Financial Data
SNY revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
SNY Risk Analysis
SNY volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
SNY Stock News
SNY stock news, market tone, recent headlines, and catalyst context.
SNY vs Drug Manufacturers - General Peers
Current peer cohort: SNY · NVS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| SNY Current stock | 68/100 | 77/100 | 64/100 | 85/100 | -0.37 | 24.14% | Current |
| NVS Novartis AG | 61/100 | 49/100 | 64/100 | 76/100 | 0.72 | 27.23% | SNY vs NVS |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for SNY: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching SNY
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for SNY
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
SNY Stock FAQ
What is SNY stock price today?
Sanofi's current stock price is $48.37. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is SNY bullish or bearish right now?
SNY's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is SNY's market cap?
SNY's market cap is $115.76B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is SNY's current P/E ratio?
SNY's current P/E ratio is 25.1 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is SNY's RSI?
SNY's 14-day RSI is 76.2 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is SNY above its 50-day and 200-day moving averages?
SNY is 13.33% from its 50-day SMA and 9.03% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is SNY's next earnings date?
SNY's next earnings date is currently listed as Feb 4, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does SNY pay a dividend?
SNY's dividend yield is 4.70% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.